Animal health company Elanco (NYSE: ELAN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 4.8% year on year to $1.24 billion. Guidance for next quarter’s revenue was better than expected at $1.10 billion at the midpoint, 0.9% above analysts’ estimates. Its non-GAAP profit of $0.26 per share was 29.5% above analysts’ consensus estimates.

Is now the time to buy ELAN? Find out in our full research report (it’s free).

StockStory’s Take

Elanco’s second quarter results were well received by the market, reflecting both strong execution and momentum in its innovation-driven portfolio. Management credited broad-based growth across Pet Health and Farm Animal segments, with U.S. Pet Health leading the way, supported by recent product launches such as Credelio Quattro and Zenrelia. CEO Jeffrey N. Simmons noted that “growth was driven by both price and volume,” with innovation adding stability and expansion to the base business, especially through geographic launches and strong uptake of new therapies.

Looking ahead, management’s updated outlook is built on expanding contributions from new products, especially the continued ramp of Credelio Quattro and Zenrelia, as well as anticipated label improvements and geographic launches. Elanco plans to increase direct-to-consumer investments and leverage its Ascend initiative to drive efficiencies and margin improvement. CFO Robert M. VanHimbergen highlighted that “as innovation scales, these products have higher margins than our total average,” while also emphasizing ongoing efforts to pay down debt and strengthen the balance sheet.

Key Insights from Management’s Remarks

Elanco’s leadership cited innovation uptake, enhanced retail execution, and operational discipline as central to the quarter’s positive performance and raised guidance.

• Pet Health innovation momentum: The U.S. Pet Health segment delivered double-digit growth, largely attributed to successful launches of Credelio Quattro and Zenrelia, which expanded both clinic and retail presence. Increased adoption of these products, including new starts and switches from competitors, fueled broader portfolio gains.
• Geographic expansion: International Pet Health revenue rose as AdTab and Zenrelia rolled out in Europe, Canada, Brazil, and Japan. Management pointed to the April launch of AdTab in the U.K. and Zenrelia’s European approval as key contributors, with more regulatory milestones expected this year.
• Farm Animal segment stability: Growth in the Farm Animal business was reinforced by strong performance in beef, poultry, and swine, with Experior highlighted for rapid adoption in heifers after FDA combo clearance. Management noted high customer retention and initial signs of U.S. herd rebuilding.
• Operational improvements and deleveraging: The company’s net leverage ratio improved to 4.0x, aided by strong cash generation, disciplined working capital management, and proceeds from royalty monetization. Elanco reaffirmed that debt paydown remains its top capital allocation focus.
• Mitigating external risks: Tariff and inflation risks were actively managed through interventions and FX tailwinds. Management estimated a reduced full-year net impact from tariffs and highlighted ongoing supply chain optimization and strategic sourcing as key mitigation levers.

Drivers of Future Performance

Management expects continued growth to be driven by ramping innovation products, expanded global launches, and margin improvement from operational initiatives.

• Innovation scale and product pipeline: Elanco’s future guidance relies on further adoption of new launches like Credelio Quattro and Zenrelia, with management raising innovation revenue targets and emphasizing upcoming launches, such as the Advantage collar and the anticipated IL-31 approval for dermatology in 2026.
• Productivity and efficiency programs: The new Ascend initiative is designed to accelerate cost efficiencies via automation, digital investments, and streamlined operations, with expected benefits to operating margins and cash flow beginning in 2026. Management also noted ongoing efforts to optimize manufacturing and reduce administrative expenses.
• Addressing market and macro risks: Management highlighted ongoing exposure to tariffs and FX volatility, but asserted that mitigating strategies, including tactical pricing, inventory management, and supply chain adjustments, are expected to offset these risks. Guidance assumes a balanced approach to potential external headwinds and competitive pressures.

Catalysts in Upcoming Quarters

In the quarters ahead, the StockStory team will closely monitor (1) the continued adoption and global rollout of key innovation products, particularly Zenrelia and Credelio Quattro; (2) the execution of the Ascend initiative and its early impact on margins and operational efficiency; and (3) the pace of deleveraging and improvements in net leverage ratio. Additionally, label updates for Zenrelia and progress toward IL-31 regulatory approval will be critical milestones.

Elanco currently trades at $17.15, up from $13.98 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.